Clinical Trials & Research
Search Clinical Trials
|Title||Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia|
|Description||The purpose of this trial is to study the side effects and best dose of vorinostat and azacitidine in treating patients with myelodysplastic syndromes or acute myeloid leukemia.|
Vorinostat may stop the growth of cancer or abnormal cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer or abnormal cells, either by killing the cells or by stopping them from dividing.
Giving vorinostat together with azacitidine may kill more cancer or abnormal cells.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older
* Patient has histologically confirmed diagnosis of 1 of the following:
-Refractory anemia (RA)
-RA with ringed sideroblasts (RARS) RA with excess blasts (RAEB)
-RAEB in transformation
-Chronic myelomonocytic leukemia
-Classified according to International Prognostic Scoring System (IPSS) criteria as intermediate-1, intermediate-2, or high-risk disease.
* Patient has ife expectancy of more than 2 months
* Patient has had no other malignancy within the past 3 years
* Patient has no HIV positivity
|Principal Investigator||Amit Verma, MD|
|Current Trial Type||Interventional|
|Montefiore Clinical Trial||No|
|CHAM Clinical Trial||No|